Huadong Medicine Co (SZSE:000963) ROCE % : 18.87% (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Huadong Medicine Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Huadong Medicine Co's annualized ROCE % for the quarter that ended in Mar. 2024 was 18.87%.

Huadong Medicine Co ROCE % Historical Data

The historical data trend for Huadong Medicine Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huadong Medicine Co ROCE % Chart

Huadong Medicine Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

28.72

24.50

17.36

16.28

16.39

Huadong Medicine Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															18.51	15.99	16.89	14.41	18.87

Huadong Medicine Co ROCE % Calculation

Huadong Medicine Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	3584.201	/	( ( (31192.203 - 10152.812)	+	(33509.362 - 10802.606) )	/ 2 )
	=	3584.201	/	( (21039.391	+	22706.756)	/ 2 )
	=	3584.201	/	21873.0735
	=	16.39 %

Huadong Medicine Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	4364.956	/	( ( (33509.362 - 10802.606)	+	(34467.844 - 10918.318) )	/ 2 )
	=	4364.956	/	( ( 22706.756	+	23549.526 )	/ 2 )
	=	4364.956	/	23128.141
	=	18.87 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Huadong Medicine Co (SZSE:000963) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Huadong Medicine Co ROCE % Related Terms

Thank you for viewing the detailed overview of Huadong Medicine Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Huadong Medicine Co (SZSE:000963) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huadong Medicine Co Ltd (SZSE:000963) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

468 Yan’an Road, Floor 7, 9 and 10, Gate No. 1, Building No. 1, Hangzhou, CHN, 310006

Website

http://www.eastchinapharm.com

Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine and genetic engineering drugs products. It is also engaged in the wholesale, retail and distribution business of Chinese and western medicine, Chinese herbal medicine, medical apparatus, and instruments. The main business of the company is divided into pharmaceutical business sales and the industry of pharmaceutical. The product portfolio of the company includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and others.

Huadong Medicine Co (SZSE:000963) Headlines

No Headlines